MoCRA's serious adverse event rule is built around a short operational deadline: 15 business days. The clock is manageable when every report enters a controlled intake channel on the day it arrives. It becomes dangerous when complaints move through resellers, marketplaces, distributors, customer-service teams, and overseas offices before anyone recognizes that the message describes a reportable medical outcome.
First decide whether the event meets the serious definition
A serious adverse event is one that results in death, a life-threatening experience, inpatient hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, an infection, or significant disfigurement. For cosmetics, significant disfigurement includes serious and persistent rashes, second- or third-degree burns, significant hair loss, and persistent or significant alteration of appearance. The definition also captures an event requiring medical or surgical intervention to prevent one of those outcomes.
A report does not need to arrive with a diagnosis or complete medical chart. The intake process should capture what is known and immediately request the missing facts: when the product was used, symptoms, treatment, hospitalization, duration, photographs if offered, product identity, lot code, other products used, and contact information for follow-up. The filing deadline cannot be paused while a brand waits for perfect information.
When the 15-business-day clock starts
The statutory filing period runs from receipt of the serious adverse event report by the Responsible Person. An effective program treats the earliest receipt anywhere in the Responsible Person's controlled intake network as the operational start and requires resellers, distributors, and customer-service teams to escalate health complaints immediately. Waiting until a regulatory specialist opens the message is not a safe deadline policy. The organization needs a timestamp it can defend and a workflow that does not lose days in internal routing.
What is submitted to the FDA
Industry reports serious cosmetic adverse events using FDA MedWatch Form 3500A through the submission channels identified by the FDA. The report includes identifiable information about the patient and reporter when available, the event and medical outcome, the suspect cosmetic product, relevant dates, and the Responsible Person. MoCRA also requires a copy of the label on or within the retail packaging. The case file should preserve the submitted form, label version, confirmation or transmission evidence, and the information used for the assessment.
The obligation continues for one year
The initial 3500A submission does not close the case. If the Responsible Person receives new medical or other information related to the original serious adverse event during the following year, that information must be submitted to the FDA within 15 business days of receipt. A functioning system therefore needs follow-up dates, open-case reminders, a place to attach new records, and a clear method for connecting each supplemental submission to the original report.
Why foreign brands lose the deadline
The most common failure is not refusal to report. It is fragmented receipt. A consumer contacts a marketplace; the marketplace forwards the message to a distributor; the distributor sends a weekly spreadsheet to the foreign brand; the brand sends it to a general consultant; and only then does someone ask whether it is serious. By that point, much of the 15-business-day period may have disappeared. Language differences, national holidays, time zones, and incomplete reseller contracts add more delay.
A managed intake channel protects the clock
A managed program creates one route from receipt to decision. Reports are timestamped, logged, screened for seriousness, escalated for missing medical facts, and assigned a filing deadline. When the event is serious, the 3500A and label copy are prepared and submitted, and the case remains open for the one-year follow-up period. FDABridge provides that complete FDA Adverse Event Management function for cosmetic Responsible Persons and foreign brands.
Need a compliant cosmetic adverse-event program?
We manage intake, seriousness assessment, FDA filings, follow-up, and audit-ready records under MoCRA.